TITLE

Fluoxetine effect on kidney water reabsorption

AUTHOR(S)
Zenaide Providello Moyses; Fausto Kigui Nakandakari; Antonio José Magaldi
PUB. DATE
April 2008
SOURCE
Nephrology Dialysis Transplantation;Apr2008, Vol. 23 Issue 4, p1173
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. The pathogenesis of hyponatraemia caused by fluoxetine(Fx) use in the treatment of depression is not well understood. It has been attributed to a SIADH, although ADH-enhanced plasma level has not yet been demonstrated in all the cases reported in humans. This experiment aimed at investigating the effect of fluoxetine on the kidney and more specifically in the inner medullary collecting duct (IMCD). Methods. (1) In vivo study: (a) 10 rats were injected daily i.p. with 10 mg/kg fluoxetine doses. After 10 days, rats were sacrificed and blood and kidneys were collected. (b) Immunoblotting studies for AQP2 protein expression in the IMCD from injected rats and in IMCD tubules suspension from 10 normal rats incubated with 10−7 M fluoxetine. (2) In vitro microperfusion study: The osmotic water permeability (Pf, μm/s) was determined in normal rats IMCD (n = 6), isolated and perfused by the standard methods. Results. In vivo study: (a) Injected rats with fluoxetine lost about 12% body weight; Na plasma level decreased from 139.3 ± 0.78 mEq/l to 134.9 ± 0.5 mEq/l (p p p In vitro microperfusion study fluoxetine increased Pf in the IMCD in the absence of ADH from the cont 7.24 ± 2.07 to Fx 15.77 ± 3.25 (p Conclusion. After fluoxetine use, the weight and plasma Na level decreased, and the K and ADH plasma levels remained unchanged, whereas the AQP2 protein abundance and water absorption in the IMCD increased, leading us to conclude that the direct effect of fluoxetine in the IMCD could explain at least in part, the hyponatraemia found sometime after this drug use in humans.
ACCESSION #
31865459

 

Related Articles

  • A Controlled Comparison of Fluoxetine and Amitriptyline in Depressed Out-patients. Young, J. P. R.; Coleman, A.; Lader, M. H. // British Journal of Psychiatry;Sep87, Vol. 151, p337 

    Fluoxetine, a selective serotonin uptake inhibitor (mean dose 73 mg each morning) was compared with amitriptyline (mean dose 122 mg at night) in a double-blind study of 64 depressed out-patients. Fifty patients completed the 6-week trial. The drugs did not differ with respect to psychiatrists'...

  • The effect of grape seed hydroalcholic extract on testosterone concentration in fluoxetine induced oxidative stress in the mouse testise. Hajizadeh, Z.; Soleimani, M.; Najafi, B.; Zarei, L. // Iranian Journal of Reproductive Medicine;Jun2014 Supplement, Vol. 12, p110 

    Introduction: The selective serotonin reuptake inhibitors (SSRI), including fluoxetine (FLX) are used for the treatment of depression and psychiatric disorders such as panic disorder and anxiety. Grape seed extract (GS extract) is a natural extract from the seed of grape that is rich in mono-,...

  • Antidepressants and suicide: risk--benefit conundrums. Healy, David; Whitaker, Chris // Journal of Psychiatry & Neuroscience;Sep2003, Vol. 28 Issue 5, p331 

    Surveys available randomized controlled trials, meta-analyses of clinical trials and epidemiological studies regarding the possibility that selective serotonin reuptake inhibitor (SSRI) antidepressants might induce suicidal tendencies in patients. Dose-dependent link between SSRI and agitation...

  • Suicidality with selective serotonin reuptake inhibitors: Valid claim? Lapierre, Yvon D. // Journal of Psychiatry & Neuroscience;Sep2003, Vol. 28 Issue 5, p340 

    Surveys relevant literature addressing the epidemiological data regarding suicidal tendencies among patients receiving selective serotonin reuptake inhibitors. Issues concerning efficacy of antidepressants; Risk of depressed patient committing suicide with prescribed antidepressants; Principles...

  • Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Vanderkooy, JD; Kennedy, Sidney H; Bagby, R Michael; Vanderkooy, J D // Canadian Journal of Psychiatry;Mar2002, Vol. 47 Issue 2, p174 

    Objective: There is no commonly accepted standard for comparing antidepressant-induced side effects. This study evaluates a clinician-administered scale, the Toronto Side Effect Scale (TSES), in a natural practice clinic.Method: We used the TSES to assess side effects...

  • Sex- and age-related differences in major depressive disorder with comorbid anxiety treated with fluoxetine. Cassano, P.; Soares, C. N.; Cohen, L. S.; Lyster, A. K.; Fava, M. // Archives of Women's Mental Health;2004, Vol. 7 Issue 3, p167 

    Objective: To examine sex- and age-related differences of treatment outcome in a cohort of outpatients with major depressive disorder (MDD), with and without comorbid anxiety, treated with fluoxetine. Methods: Outpatients with a SCID-diagnosis of MDD aged 18 to 65 years were treated openly with...

  • Corticolimbic Functional Connectivity in Adolescents with Bipolar Disorder. Fei Wang; Bobrow, Laurel; Jie Liu; Spencer, Linda; Blumberg, Hilary P. // PLoS ONE;Nov2012, Vol. 7 Issue 11, Special section p1 

    Convergent evidence supports regional dysfunction within a corticolimbic neural system that subserves emotional processing and regulation in adolescents and adults with bipolar disorder (BD), with abnormalities prominent within the amygdala and its major anterior paralimbic cortical connection...

  • PAINFUL TRUTH.  // Time;2/9/2004, Vol. 163 Issue 6, p80 

    Reports that new research suggests that depression and physical pain often go hand in hand. Details of a study involving a group of patients who were not responding to antidepressants after three months of treatment; Finding that the drugs were most likely to fail those who were in pain at the...

  • How do SSRIs help patients with irritable bowel syndrome? Creed, F. // Gut;Aug2006, Vol. 55 Issue 8, p1065 

    The article discusses the use of selective serotonin reuptake inhibitor (SSRI) for the treatment of depression patients with irritable bowel syndrome (IBS). In case of non-depressed IBS patients, placebo was found to be better than fluoxetine for improving the condition of patients. SSRI...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics